NEW YORK (GenomeWeb News) – Shares of Luminex and Sequenom both fell by double digits today following disappointing first-quarter financial reports on Thursday.

In mid-afternoon trade on Friday, shares of Luminex had fallen nearly 13 percent to $15.49 while those of Sequenom had dropped more than 16 percent to $5.08.

Luminex yesterday reported that its second-quarter revenues increased 14 percent to $27.8 million, but this did not meet analyst estimates of $29.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.